stockrow
Monday 9 November 2026
Export ORMP’s income statement to Excel — free account
Oramed Pharmaceuticals Inc.
ORMPOramed Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 49.3% from fiscal 2023.
- Revenue
- +193.3%
- EPS
- +493.8%
- Free cash flow
- +94.3%
Quarter to June 2026, against a year earlier
3.86
0.03
−0.77%
Follow ORMP
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
22.01 | 6.60 | 6.23 | 4.77 | |
Current Ratio |
22.25 | 6.98 | 6.45 | 4.98 | |
Net Debt/EBITDA |
56.21 | 22.31 | 18.14 | 18.51 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.03) | (0.05) | (0.08) | 0.00 | |
Capex/Depreciation |
0.00 | (0.07) | (0.17) | (0.06) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.04) | (0.01) | (0.07) | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.01) | (0.07) | 0.00 | |
Cash per Share |
3.23 | 3.04 | 1.61 | 1.23 | |
Shareholders Equity per Share |
4.85 | 4.82 | 5.84 | 7.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.85 | 4.82 | 5.84 | 7.74 | |
Free Cash Flow |
(1.62) | (0.47) | (2.92) | (0.20) | |
Working Capital |
130.00 | 114.19 | 57.59 | 42.68 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
117.95 | 102.15 | 37.58 | 1.24 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 0.52 | |
Average Payables |
4.95 | 6.16 | 6.92 | 5.35 | |
Average Assets |
192.79 | 193.07 | 208.19 | 265.66 | |
Average Common Equity |
178.93 | 172.55 | 189.09 | 235.53 |
Columns are period end dates · fundamentals updated 2 Nov 2026